Navigation Links
Genta Announces Second Quarter 2008 Financial Results and Conference Call
Date:7/31/2008

BERKELEY HEIGHTS, N.J., July 31 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced today that the Company will release its second quarter 2008 financial results on Thursday, August 7, 2008. Genta management will host a conference call and live audio webcast to discuss these financial results and corporate activities at 8:00 am EDT.

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (706) 679-3140 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html

For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is 57549066.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration ("FDA") or European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its products or product candidates;

-- the Company's ability to enter into and successfully execute license and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the Company's risk of bankruptcy if it is unsuccessful in obtaining such financing or in securing shareholder approval to increase the number of shares authorized for issuance under the Company's certificate of incorporation, as required by the transactional documents in our recent financing;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and any proposed settlement of such litigation; and

-- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Genta Investor Relations

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
2. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
3. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
4. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
5. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
6. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
7. Dr. Elizabeth Brown Joins Argenta TEC
8. Syngenta To Build Major Global Biotech Research Center in Beijing, China
9. Genta Restructures Operations to Focus on Priority Initiatives
10. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
11. Auditors for Genta Incorporated Express Going Concern Qualification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to ... and is planned for further growth in 2017. Extractable & Leachable evaluations have ...
(Date:1/18/2017)... IL (PRWEB) , ... January 18, 2017 , ... ... on January 24th, 2017, to sell research and genetic testing lab equipment from ... service in the Northwest and Northeast regions of the United States. This 1-day ...
Breaking Biology Technology:
(Date:1/13/2017)... PORT WASHINGTON, N.Y. , Jan. 13, 2017 ... provider of technology solutions for the homecare industry, ... appointment of homecare industry expert, Justin Jugs, as ... Justin brings more than 15 years of homecare ... the team in developing strategic plans to align ...
(Date:1/12/2017)... January 12, 2017 A new report by Allied Market Research, ... global biometric technology market is expected to generate revenue of $10.72 billion by 2022, ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
Breaking Biology News(10 mins):